n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)

Santarus Extends Maturity Of $25 Million Revolving Line Of Credit To July 2013

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it has extended the maturity date of its $25 million revolving line of credit with Comerica Bank from July 11, 2011 to July 11,...

Santarus Inc. Q2 2010 Earnings Call Transcript

Santarus Inc. Q2 2010 Earnings Call Transcript

Santarus Reports Second Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2010.

Santarus To Present At BMO Capital Markets 10th Annual Focus On Healthcare Conference

Santarus To Present At BMO Capital Markets 10th Annual Focus On Healthcare Conference

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus To Hold Second Quarter 2010 Financial Results Conference Call On August 2

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release second quarter 2010 financial results after market close on Monday, August 2, 2010.

Santarus Announces Launch Of Prescription ZEGERID Authorized Generic And Company Restructuring

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of...

Santarus Begins Enrollment In Phase III Clinical Program For Rifamycin SV MMX In Travelers’ Diarrhea

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of ...

Santarus To Present At The Jefferies 2010 Global Life Sciences Conference

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Trico Marine Services, Sequenom: Early Volume Plays

Trico Marine Service was one of several stocks trading near $5 poised to move on above-average volume Friday.

Santarus Inc. Q1 2010 Earnings Call Transcript

Santarus Inc. Q1 2010 Earnings Call Transcript

Santarus Reports First Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2010.

Santarus To Hold First Quarter 2010 Financial Results Conference Call On May 6

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it will release first quarter 2010 financial results after market close on Thursday, May 6, 2010.

Dynavax, Santarus: Early Volume Plays

Dynavas and Santarus were among stocks trading near $5 were poised to move on above-average volume Thursday

Santarus Announces District Court Ruling In Par Litigation

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that the U.

Santarus Announces Launch Of ZEGERID OTC By Schering-Plough Consumer HealthCare

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc.

Santarus Announces Completion Of Enrollment In U.S. Phase III Clinical Study For Budesonide MMX

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.

Santarus To Present At March Investment Conferences

Santarus To Present At March Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus To Hold Fourth Quarter And Full Year 2009 Financial Results Conference Call On March 3

Santarus To Hold Fourth Quarter And Full Year 2009 Financial Results Conference Call On March 3

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release fourth quarter and full year 2009 financial results after market close on Wednesday, March 3, 2010.

Santarus, JA Solar: Early Volume Plays

Santarus, JA Solar: Early Volume Plays

Momentum favorites biotech and solar are being trading heavily in the week's first pre-market session.

Delta, Walgreen, Diedrich Coffee Are Big Movers

Delta, Walgreen, Diedrich Coffee Are Big Movers

Delta, Walgreen, Diedrich Coffee, GameStop are among big market movers Wednesday

Vertex Raising Money -- Again!: BioBuzz

Vertex Raising Money -- Again!: BioBuzz

Hep C drug maker could be adding $400 million-plus to its coffers with a new stock offering.

Premarket Roundup: McDonald's, Santarus

Premarket Roundup: McDonald's, Santarus

Premarket roundup: McDonald's management team strong, Santarus jumps after FDA approval

Ahead Of The Bell: Santarus Soars On OTC Zegerid

Ahead Of The Bell: Santarus Soars On OTC Zegerid

Santarus shares soar in premarket trading following FDA approval of OTC Zegerid

Dyax, RF Micro: Early Volume Plays

Dyax, RF Micro: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session

FDA Approves Two New Drugs: BioBuzz

FDA Approves Two New Drugs: BioBuzz

Dyax and Merck/Santarus get FDA approvals. The U.S. Food and Drug Administration approved two drugs Tuesday night -- a prescription drug for a rare, genetic disorder and an over-the-counter treatment for heartburn.

FDA Approves OTC Version Of Heartburn Drug Zegerid

FDA Approves OTC Version Of Heartburn Drug Zegerid

Merck and Santarus say FDA approves over-the-counter sales of Santarus heartburn drug Zegerid

Biotech Stock Mailbag: Cardium Therapeutics

Biotech Stock Mailbag: Cardium Therapeutics

The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.

Health Winners & Losers: Acadia

Shares of the biopharmaceutical company slid after it posted a widened quarterly loss and slashed staff.

Adolor, Pfizer Ink R&D Deal

The two will jointly develop and market two investigational pain relievers.

Santarus, Glaxo Ink Zegerid Deal

U.K.-based Glaxo will develop and commercialize Zegerid products in a number of non-U.S. markets.